Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN

Exchange Traded Concepts LLC purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,768 shares of the company’s stock, valued at approximately $970,000.

A number of other large investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after buying an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after acquiring an additional 15,405 shares during the last quarter. Intech Investment Management LLC grew its position in LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio purchased a new stake in LivaNova during the first quarter valued at about $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on LIVN shares. Robert W. Baird set a $75.00 price objective on LivaNova in a report on Tuesday, December 16th. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research report on Wednesday, February 25th. KeyCorp began coverage on shares of LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Mizuho boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $74.78.

LivaNova Stock Performance

Shares of LIVN opened at $63.79 on Friday. The stock’s 50-day moving average is $64.94 and its two-hundred day moving average is $60.36. The stock has a market cap of $3.49 billion, a PE ratio of -14.30 and a beta of 0.97. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $71.92. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.92 million during the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.